[{"orgOrder":0,"company":"IVERIC bio","sponsor":"Opus Genetics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AAv-based Gene Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"IVERIC bio \/ Opus Genetics","highestDevelopmentStatusID":"4","companyTruncated":"IVERIC bio \/ Opus Genetics"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ IVERIC bio","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ IVERIC bio"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Financing","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Hercules Capital"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ DelSiTech"}]
Find Clinical Drug Pipeline Developments & Deals by IVERIC bio
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
